NCT05964868View on ClinicalTrials.gov

Efficacy of Liposomal Bupivacaine Post Septorhinoplasty

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
RhinoplastyPain Management
Interventions
DRUG

Liposomal Bupivacaine

Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.

DRUG

0.25% bupivacaine with 1:200,000 epinephrine

Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.

OTHER

Placebo - Saline solution

This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.

Trial Locations (1)

17033

Jessyka Lighthall, Hershey

All Listed Sponsors
lead

Jessyka Lighthall

OTHER